Have a feature idea you'd love to see implemented?
Let us know!
ADMA Adma Biologics Inc
Price (delayed)
$21.3
Market cap
$5.04B
P/E Ratio
73.45
Dividend/share
N/A
EPS
$0.29
Enterprise value
$5.05B
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at
Highlights
The gross profit has soared by 160% YoY and by 23% from the previous quarter
The company's net income has surged by 96% QoQ
Key stats
What are the main financial stats of ADMA
Market
Valuations
Earnings
Shares outstanding
236.39M
Market cap
$5.04B
Enterprise value
$5.05B
Price to earnings (P/E)
73.45
Price to book (P/B)
21.41
Price to sales (P/S)
13.05
EV/EBIT
55.74
EV/EBITDA
51.11
EV/Sales
13.19
Revenue
$382.81M
EBIT
$90.62M
EBITDA
$98.83M
Free cash flow
$79.39M
Per share
Balance sheet
Liquidity
EPS
$0.29
Free cash flow per share
$0.34
Book value per share
$0.99
Revenue per share
$1.63
TBVPS
$1.65
Total assets
$390.62M
Total liabilities
$158.73M
Debt
$102.52M
Equity
$231.89M
Working capital
$273.3M
Debt to equity
0.44
Current ratio
7.09
Quick ratio
3.05
Net debt/EBITDA
0.16
Margins
Efficiency
Dividend
EBITDA margin
25.8%
Gross margin
48.9%
Net margin
17.8%
Operating margin
30%
Return on assets
18.8%
Return on equity
38.4%
Return on invested capital
24.7%
Return on capital employed
26.2%
Return on sales
23.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADMA stock price
How has the Adma Biologics stock price performed over time
Intraday
-0.33%
1 week
5.45%
1 month
36.36%
1 year
440.61%
YTD
371.24%
QTD
6.55%
Financial performance
How have Adma Biologics's revenue and profit performed over time
Revenue
$382.81M
Gross profit
$187.31M
Operating income
$114.89M
Net income
$68.13M
Gross margin
48.9%
Net margin
17.8%
The gross profit has soared by 160% YoY and by 23% from the previous quarter
The company's net income has surged by 96% QoQ
The company's net margin has surged by 70% QoQ
ADMA's revenue has surged by 63% year-on-year and by 16% since the previous quarter
Growth
What is Adma Biologics's growth rate over time
Valuation
What is Adma Biologics stock price valuation
P/E
73.45
P/B
21.41
P/S
13.05
EV/EBIT
55.74
EV/EBITDA
51.11
EV/Sales
13.19
The EPS has surged by 93% since the previous quarter
The price to book (P/B) is 68% higher than the last 4 quarters average of 12.8
The equity has surged by 53% year-on-year and by 23% since the previous quarter
ADMA's price to sales (P/S) is 167% higher than its 5-year quarterly average of 4.9 and 79% higher than its last 4 quarters average of 7.3
ADMA's revenue has surged by 63% year-on-year and by 16% since the previous quarter
Efficiency
How efficient is Adma Biologics business performance
The company's return on assets has surged by 90% QoQ
ADMA's ROE has soared by 74% QoQ
The company's return on invested capital has surged by 54% QoQ
The return on sales has grown by 32% since the previous quarter
Dividends
What is ADMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADMA.
Financial health
How did Adma Biologics financials performed over time
Adma Biologics's total assets is 146% more than its total liabilities
ADMA's quick ratio is up by 21% YoY and by 14% QoQ
Adma Biologics's total liabilities has decreased by 20% YoY and by 16% QoQ
The company's debt is 56% lower than its equity
The equity has surged by 53% year-on-year and by 23% since the previous quarter
Adma Biologics's debt to equity has shrunk by 53% YoY and by 37% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.